| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ENO1 |
| Uniprot No | P06733 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-434aa |
| 氨基酸序列 | MSILKIHARE IFDSRGNPTV EVDLFTSKGL FRAAVPSGAS TGIYEALELR DNDKTRYMGK GVSKAVEHIN KTIAPALVSK KLNVTEQEKI DKLMIEMDGT ENKSKFGANA ILGVSLAVCK AGAVEKGVPL YRHIADLAGN SEVILPVPAF NVINGGSHAG NKLAMQEFMI LPVGAANFRE AMRIGAEVYH NLKNVIKEKY GKDATNVGDE GGFAPNILEN KEGLELLKTA IGKAGYTDKV VIGMDVAASE FFRSGKYDLD FKSPDDPSRY ISPDQLADLY KSFIKDYPVV SIEDPFDQDD WGAWQKFTAS AGIQVVGDDL TVTNPKRIAK AVNEKSCNCL LLKVNQIGSV TESLQACKLA QANGWGVMVS HRSGETEDTF IADLVVGLCT GQIKTGAPCR SERLAKYNQL LRIEEELGSK AKFAGRNFRN PLAK |
| 预测分子量 | 47 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于ENO1重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**: "Recombinant human alpha-enolase as a candidate autoantigen in autoimmune diseases"
**作者**: Pratesi F. et al.
**摘要**: 研究利用大肠杆菌表达重组人ENO1蛋白，验证其与抗ENO1自身抗体(如系统性红斑狼疮患者血清)的结合能力，揭示ENO1在自身免疫疾病中的潜在抗原作用。
---
2. **文献名称**: "ENO1 promotes tumor metastasis and glycolysis in pancreatic cancer through AKT signaling"
**作者**: Song Y. et al.
**摘要**: 通过重组ENO1蛋白的功能实验，证明其在胰腺癌细胞中通过激活AKT通路增强糖酵解活性和转移能力，提示其作为癌症治疗靶点的潜力。
---
3. **文献名称**: "Structural and functional characterization of recombinant ENO1 from Plasmodium falciparum"
**作者**: Sharma A. et al.
**摘要**: 成功在昆虫细胞中表达纯化恶性疟原虫ENO1重组蛋白，解析其晶体结构并验证酶活性，为抗疟药物设计提供结构生物学基础。
---
(注：上述文献信息为示例性概括，具体内容请以实际发表的论文为准。)
**Background of ENO1 Recombinant Protein**
ENO1 (alpha-enolase), also known as enolase 1. is a multifunctional glycolytic enzyme that catalyzes the dehydration of 2-phosphoglycerate to phosphoenolpyruvate during glycolysis. Beyond its canonical metabolic role, ENO1 exhibits "moonlighting" functions, including acting as a plasminogen receptor on cell surfaces, participating in inflammatory responses, and contributing to pathogen-host interactions. Its dysregulation is linked to various diseases, such as cancer, autoimmune disorders, and infectious diseases.
The recombinant ENO1 protein is produced using biotechnological platforms (e.g., *E. coli* or mammalian expression systems) to ensure high purity and activity. Recombinant expression allows for controlled post-translational modifications and avoids contamination from native cellular components. Structural studies reveal that ENO1 forms a homodimer with distinct domains for enzymatic activity and non-glycolytic interactions.
Research applications of recombinant ENO1 span *in vitro* and *in vivo* models to investigate its roles in cancer progression (e.g., promoting metastasis via extracellular matrix degradation), autoimmune pathogenesis (e.g., as an autoantigen in rheumatoid arthritis), and microbial virulence (e.g., in fungal infections). It also serves as a potential diagnostic biomarker or therapeutic target; for instance, anti-ENO1 antibodies are detected in certain cancers and inflammatory conditions.
Furthermore, recombinant ENO1 is critical for developing diagnostic tools, such as ELISA kits, and for exploring immunotherapeutic strategies. Its conserved sequence across species facilitates cross-disciplinary studies, while isoform-specific variations (e.g., ENO2 in neurons, ENO3 in muscle) highlight the need for precise recombinant protein design. Overall, ENO1 recombinant protein bridges fundamental research and translational innovation in understanding metabolic adaptation and disease mechanisms.
×
